CureVac N.V. (CVAC)

CureVac Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	70.74	535.18	53.76	67.42	102.99	48.87
Revenue Growth (YoY)	-86.98%	895.54%	-20.26%	-34.54%	110.74%	180.61%
Cost of Revenue	4.75	105.63	116.21	158.97	215.27	14.17
Gross Profit	65.99	429.55	-62.45	-91.55	-112.28	34.7
Selling, General & Admin	88.53	74.34	95.74	107.07	102.26	54.29
Research & Development	154.87	153.03	115.72	62.55	815.91	113.81
Other Operating Expenses	-359.48	-7.6	-7.8	-36.66	-0.1	0.15
Operating Expenses	-116.08	219.77	203.67	132.96	918.07	168.25
Operating Income	182.08	209.78	-266.12	-224.51	-1,030	-133.55
Interest Expense	-6.18	-	-	-2.3	-6.79	-22.1
Interest & Investment Income	12.76	12.36	2.02	15.41	0.08	2.07
Currency Exchange Gain (Loss)	0.84	0.84	-1.21	0.87	6.15	-
Other Non Operating Income (Expenses)	-0	-	13.43	-13.68	0.32	-
EBT Excluding Unusual Items	189.5	222.98	-251.88	-224.21	-1,031	-153.58
Merger & Restructuring Charges	-32.1	-32.1	-	-	-	-
Asset Writedown	-	-	-8.09	-24.95	-22.81	-
Other Unusual Items	-	-	-	-	640.9	23.74
Pretax Income	157.4	190.88	-259.97	-249.16	-412.5	-129.85
Income Tax Expense	28.57	28.7	0.2	-0.13	-0.78	-0.73
Net Income	128.82	162.19	-260.17	-249.03	-411.72	-129.12
Net Income to Common	128.82	162.19	-260.17	-249.03	-411.72	-129.12
Shares Outstanding (Basic)	161	224	221	189	186	132
Shares Outstanding (Diluted)	161	224	221	189	186	132
Shares Change (YoY)	-38.70%	1.57%	16.84%	1.65%	40.71%	36.72%
EPS (Basic)	0.80	0.72	-1.18	-1.32	-2.21	-0.98
EPS (Diluted)	0.80	0.72	-1.18	-1.32	-2.21	-0.98
Free Cash Flow	-124.13	87.54	-320.21	-374.2	-857.35	486.07
Free Cash Flow Per Share	-0.77	0.39	-1.45	-1.98	-4.61	3.68
Gross Margin	93.29%	80.26%	-116.17%	-135.79%	-109.02%	71.00%
Operating Margin	257.38%	39.20%	-495.04%	-333.00%	-1000.44%	-273.27%
Profit Margin	182.11%	30.30%	-483.96%	-369.37%	-399.76%	-264.21%
Free Cash Flow Margin	-175.47%	16.36%	-595.64%	-555.03%	-832.46%	994.61%
EBITDA	193.69	222.56	-249.33	-205.82	-1,020	-123.1
EBITDA Margin	273.81%	41.59%	-	-	-	-251.88%
D&A For EBITDA	11.62	12.78	16.79	18.69	10.31	10.46
EBIT	182.08	209.78	-266.12	-224.51	-1,030	-133.55
EBIT Margin	257.38%	39.20%	-	-	-	-273.27%
Effective Tax Rate	18.15%	15.03%	-	-	-	-

Updated Nov 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q